488 related articles for article (PubMed ID: 9710362)
1. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
2. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
5. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
6. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
7. Complete remission of macroprolactinoma after long-term medical therapy with dopamine agonists.
Iglesias P; Díez JJ
QJM; 2011 Aug; 104(8):721-2. PubMed ID: 20663808
[No Abstract] [Full Text] [Related]
8. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
9. [Bromocriptine treatment of invasive giant prolactinomas prior to comprehensive treatments: results of a long-term follow up].
Zhang HW; Yu CJ; Sun W; Yang J; Yan CX; Cun EH
Zhonghua Wai Ke Za Zhi; 2006 Nov; 44(22):1555-7. PubMed ID: 17359664
[TBL] [Abstract][Full Text] [Related]
10. Gamma knife radiosurgery for medically and surgically refractory prolactinomas.
Pouratian N; Sheehan J; Jagannathan J; Laws ER; Steiner L; Vance ML
Neurosurgery; 2006 Aug; 59(2):255-66; discussion 255-66. PubMed ID: 16883166
[TBL] [Abstract][Full Text] [Related]
11. Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.
Jones SE; James RA; Hall K; Kendall-Taylor P
Clin Endocrinol (Oxf); 2000 Oct; 53(4):529-34. PubMed ID: 11012580
[TBL] [Abstract][Full Text] [Related]
12. Acute complications of dopamine agonist treatment for macroprolactinoma - how uncommon?
Nadesapillai S; Balcere I; Kaye AH; Tress BM; Colman PG
J Clin Neurosci; 2004 Nov; 11(8):825-8. PubMed ID: 15519856
[TBL] [Abstract][Full Text] [Related]
13. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
15. Chiasmal herniation as a complication of bromocriptine therapy.
Taxel P; Waitzman DM; Harrington JF; Fagan RH; Rothfield NF; Chen HH; Malchoff CD
J Neuroophthalmol; 1996 Dec; 16(4):252-7. PubMed ID: 8956160
[TBL] [Abstract][Full Text] [Related]
16. [Results of treatment for male prolactinomas].
Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
[TBL] [Abstract][Full Text] [Related]
17. Treatment of macroprolactinomas at Auckland Hospital 1975-91.
Wallace EA; Holdaway IM
N Z Med J; 1995 Feb; 108(994):50-2. PubMed ID: 7885646
[TBL] [Abstract][Full Text] [Related]
18. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
19. Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
Bronstein MD
Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):130-1. PubMed ID: 16932269
[No Abstract] [Full Text] [Related]
20. Management of resistant prolactinomas.
Olafsdottir A; Schlechte J
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
